Division of Cardiology, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA; Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Division of Cardiology, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA; Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
JACC Clin Electrophysiol. 2023 Jan;9(1):73-84. doi: 10.1016/j.jacep.2022.08.023. Epub 2022 Nov 30.
Guidelines for electrophysiology study (EPS) and catheter ablation in Wolff-Parkinson-White (WPW) are age based, but size may be a more relevant factor in determination of outcomes.
The goal of this study was to evaluate the association of patient weight with outcomes of catheter ablation for pediatric WPW.
A multicenter retrospective cohort study was performed on children aged 1 to 21 years with WPW and first-time EPS from April 2016 to December 2019 recorded in the IMPACT (Improving Pediatric and Adult Congenital Treatment) registry, excluding those with congenital heart disease, cardiomyopathy, and >1 ablation target. A weight threshold of 30 kg was selected, representing 1 SD below the cohort mean. The primary outcome was major adverse events (MAEs); additional outcomes included deferred ablation, use of cryoablation, and ablation success.
A total of 4,456 subjects from 84 centers were evaluated, with 14% weighing <30 kg. Subjects weighing <30 kg were more likely to have preprocedural supraventricular tachycardia (45% vs 29%; P < 0.001) and less likely to have right septal accessory pathways (25% vs 33%; P < 0.001). MAEs were rare, although with higher incidence in the <30 kg cohort (0.3% vs 0.05%; P = 0.04). No difference was seen in likelihood of deferred ablation (9% vs 12%; P = 0.07) or use of cryoablation (11% vs 11%; P = 0.70). Success was higher in the <30 kg cohort: 95% vs 92% (P = 0.009). This effect persisted after adjusting for covariates (odds ratio: 1.6; 95% CI: 1.01-2.70; P = 0.046).
Weight <30 kg was associated with a small but elevated risk of MAEs. Rates of deferred ablation and cryoablation were similar. Adjusting for factors (including accessory pathway type and location), weight <30 kg remained an independent predictor of acute success.
针对沃夫-帕金森-怀特(WPW)综合征的电生理研究(EPS)和导管消融的指南是基于年龄的,但在确定结果方面,体型可能是一个更相关的因素。
本研究的目的是评估患者体重与儿科 WPW 导管消融治疗结果的关系。
对 2016 年 4 月至 2019 年 12 月期间在 IMPACT(改善儿科和成人先天性治疗)注册中心记录的年龄在 1 至 21 岁的 WPW 综合征和首次 EPS 的儿童进行了一项多中心回顾性队列研究,排除了患有先天性心脏病、心肌病和>1 个消融靶点的儿童。选择 30 公斤的体重阈值,代表队列平均值的 1 个标准差以下。主要不良事件(MAE)是主要终点;其他结果包括延迟消融、使用冷冻消融和消融成功。
共评估了 84 个中心的 4456 名患者,其中 14%的患者体重<30 公斤。体重<30 公斤的患者更有可能在术前出现室上性心动过速(45%比 29%;P<0.001),而右侧间隔旁路的可能性较小(25%比 33%;P<0.001)。MAE 罕见,但在体重<30 公斤的患者中发生率更高(0.3%比 0.05%;P=0.04)。延迟消融的可能性(9%比 12%;P=0.07)或使用冷冻消融(11%比 11%;P=0.70)无差异。体重<30 公斤的患者成功率更高:95%比 92%(P=0.009)。这种影响在调整了协变量后仍然存在(优势比:1.6;95%置信区间:1.01-2.70;P=0.046)。
体重<30 公斤与 MAE 风险略有增加有关。延迟消融和冷冻消融的发生率相似。在调整了包括旁路类型和位置在内的因素后,体重<30 公斤仍然是急性成功的独立预测因素。